Inhibiting the hormone somatostatin may be a new treatment strategy to prevent dangerous blood glucose drops in type 1 ... People with type 1 diabetes have a lack of insulin but also glucagon.

Objective—Somatostatin (SST) is secreted by islet δ-cells and by extraislet neuroendocrine cells. SST receptors have been identified on α- and β-cells, and exogenous SST inhibits insulin and ...

Glucagon has the opposite effect in the body to insulin, which lowers blood glucose. Both hormones are produced in the pancreas. People with type 1 diabetes have a lack of insulin but also glucagon.

On days 2–5, pancreatic endocrine clamps were performed using somatostatin infusions of somatostatin and/or selective replacement of insulin and glucagon; day 2, GLP-1 plus basal insulin and ...

Blocking the somatostatin receptors could potentially restore the secretion of glucagon, providing a promising therapeutic strategy for the management of hypoglycemia in type 1 diabetes patients ...

The researchers examined groups of hormone-producing cells from the pancreas of both humans and mice. They were able to show that in type 1 diabetes, these islets are unable to release glucagon when ...

Blood glucose levels are mainly regulated by the opposing actions of insulin and glucagon—insulin lowers blood sugar levels, while glucagon raises it. Glucagon is regulated by the inhibitory effects ...

Researchers found that blocking somatostatin restores glucagon release in type 1 diabetes, potentially preventing severe hypoglycemia. The study highlights the relationship between pancreatic ...

Glucagon has the opposite effect in the body to insulin, which lowers blood glucose. Both hormones are produced in the pancreas. People with type 1 diabetes have a lack of insulin but also glucagon.